Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Kang
Sokbom
S
Branch of Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. sokbom@ncc.re.kr
Kim
Tae-Joong
TJ
Seo
Sang-Soo
SS
Kim
Byoung-Gie
BG
Bae
Duk-Soo
DS
Park
Sang-Yoon
SY
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000097:blood*; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D018572:Disease-Free Survival; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies
D018394:CA-125 Antigen